scholarly journals Survival Outcome and Prognostic Factors for Pancreatic Acinar Cell Carcinoma: Retrospective Analysis from the German Cancer Registry Group

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6121
Author(s):  
Ekaterina Petrova ◽  
Joachim Wellner ◽  
Anne K. Nording ◽  
Rüdiger Braun ◽  
Kim C. Honselmann ◽  
...  

Background: Pancreatic acinar cell carcinoma (PACC) is a distinct type of pancreatic cancer with low prevalence. We aimed to analyze prognostic factors and survival outcome for PACC in comparison to pancreatic ductal adenocarcinoma (PDAC), based on data from the German Cancer Registry Group. Methods: Patients with PACC and PDAC were extracted from pooled data of the German clinical cancer registries (years 2000 to 2019). The distribution of demographic parameters, tumor stage and therapy modes were compared between PACC and PDAC. The Kaplan–Meier method and Cox regression analysis were used to delineate prognostic factors for PACC. Propensity score matching was used to compare survival between PACC and PDAC. Results: There were 233 (0.44%) patients with PACC out of 52,518 patients with pancreatic malignancy. Compared to PDAC, patients with PACC were younger (median age 66 versus 70, respectively, p < 0.001) and the percentage of males was higher (66.1% versus 53.3%, respectively, p < 0.001). More patients were resected with PACC than with PDAC (56.2% versus 38.9%, respectively, p < 0.001). The estimated overall median survival in PACC was 22 months (95% confidence interval 15 to 27), compared to 12 months (95% confidence interval 10 to 13) in the matched PDAC cohort (p < 0.001). Surgical resection was the strongest positive prognostic factor for PACC after adjusting for sex, age, and distant metastases (hazard ratio 0.34, 95% confidence interval 0.22 to 0.51, p < 0.001). There was no survival benefit for adjuvant therapy in PACC. Conclusions: PACC has overall better prognosis than PDAC. Surgical resection is the best therapeutic strategy for PACC and should be advocated even in advanced tumor stages.

HPB ◽  
2019 ◽  
Vol 21 (6) ◽  
pp. 687-694 ◽  
Author(s):  
Karenia Landa ◽  
Kyle Freischlag ◽  
Daniel P. Nussbaum ◽  
Linda M. Youngwirth ◽  
Dan G. Blazer

2007 ◽  
Vol 18 (2) ◽  
pp. 95-102 ◽  
Author(s):  
György Illyés ◽  
Andrea Luczay ◽  
Gábor Benyó ◽  
Attila Kálmán ◽  
Katalin Borka ◽  
...  

2007 ◽  
Vol 106 (8) ◽  
pp. 669-672 ◽  
Author(s):  
Yang-Chao Lin ◽  
Po-Huang Lee ◽  
Yu-Tung Yao ◽  
Jong-Kai Hsiao ◽  
Jin-Chuan Sheu ◽  
...  

1996 ◽  
Vol 3 (1) ◽  
pp. 71-73 ◽  
Author(s):  
Takashi Ohsato ◽  
Ryuichi Mibu ◽  
Eishi Nagai ◽  
Hiroshi Satoh ◽  
Mitsuo Iida ◽  
...  

Suizo ◽  
2019 ◽  
Vol 34 (5) ◽  
pp. 270-278
Author(s):  
Taro MASHIKO ◽  
Kohei TAJIMA ◽  
Naoki YAZAWA ◽  
Yoshihito MASUOKA ◽  
Toshio NAKAGOHRI

2021 ◽  
Author(s):  
Jianying Xu ◽  
Wenlong Guan ◽  
Shixun Lu ◽  
Xiaoli Wei ◽  
Wenjie Shi ◽  
...  

Abstract Background: Pancreatic acinar cell carcinoma (PACC) is rare and its appropriate treatment remains unknown dued to limited and selection-biased dataMethods: The data on clinicopathologic characteristics, molecular alteration, treatment and survival of patients diagnosed as PACC in Sun Yat-sen university cancer center from 2005 to 2020 were collected. We explored the optimal treatment by co-analyzing our results and published literatures.Results: 22 PACC patients were enrolled. 8/17 non-metastatic patients received adjuvant chemotherapy. The patients receiving fluoropyrimidine-based regimen (n=3) had better mDFS than those with gemcitabine-based regimen (n=5) (unreached vs. 27 months). 8 metastatic patients received 1st-line chemotherapy. 4/5 patients with FOLFIRINOX regimen achieved partial response (PR) and 3 patients with AG (albumin paclitaxel+gemcitabine) regimen got progressive disease (PD). 4 patients received 2nd-line chemotherapy. 2 patients with FOLFIRINOX regimen achieved PR while 2 patients with AG regimen got PD. One patient who had responded to 1st-line FOLFIRINOX regimen received Olaparib as maintenance treatment for 5 months with good tolerance. 31 published literatures and a total of 86 cases were included in the co-analysis. Objective response rate of 1st-line fluoropyrimidine-based regimen (n=47) was higher than that of gemcitabine-based regimen (n=39) (59.6% vs.15.3%, P<0.001). 8/11 patients treated with FOLFIRINOX regimen achieved PR. Conclusions: The benefit of adjuvant chemotherapy remained unclear; however, fluoropyrimidine-based chemotherapy deserves attention. For metastatic patients, fluorouracil-based regimen such as FOLFIRINOX is preferred, and maintenance treatment of PARP inhibitors after effective platinum-containing treatment for BRAC mutation patients is worthy of exploration.


Sign in / Sign up

Export Citation Format

Share Document